Stockscreener 앱 받기
223.47
0.04%
-0.41
전일 마감가:
$223.06
열려 있는:
$221.71
하루 거래량:
215.94K
Relative Volume:
0.32
시가총액:
$11.49B
수익:
$708.24M
순이익/손실:
$-188.30M
주가수익비율:
-59.76
EPS:
-3.7392
순현금흐름:
$-70.99M
1주 성능:
+21.22%
1개월 성능:
+31.37%
6개월 성능:
+59.94%
1년 성능:
+98.80%
1일 변동 폭
$221.71
$227.45
1주일 범위
$183.86
$234.29
52주 변동 폭
$96.09
$234.29
Axsome Therapeutics Inc Stock (AXSM) Company Profile
명칭
Axsome Therapeutics Inc
전화
(212) 332-3241
주소
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Compare AXSM vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
223.27 | 11.48B | 708.24M | -188.30M | -70.99M | -3.7392 |
VRTX
Vertex Pharmaceuticals Inc
|
425.19 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
720.55 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
811.76 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.29 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
315.86 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2026-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-01 | 개시 | B. Riley Securities | Buy |
| 2025-09-03 | 재개 | Wells Fargo | Overweight |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-06-03 | 개시 | Oppenheimer | Outperform |
| 2025-04-07 | 개시 | Jefferies | Buy |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-12-31 | 재확인 | Mizuho | Outperform |
| 2024-09-03 | 개시 | Wells Fargo | Overweight |
| 2024-08-06 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-07-22 | 개시 | Needham | Buy |
| 2024-04-29 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | 개시 | Robert W. Baird | Outperform |
| 2024-02-06 | 개시 | UBS | Buy |
| 2024-01-25 | 개시 | RBC Capital Mkts | Outperform |
| 2023-12-13 | 개시 | Citigroup | Buy |
| 2023-08-08 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-01-05 | 개시 | Piper Sandler | Neutral |
| 2022-11-01 | 개시 | Loop Capital | Buy |
| 2022-09-07 | 재개 | Mizuho | Buy |
| 2021-08-10 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | 개시 | Berenberg | Buy |
| 2021-01-08 | 개시 | Jefferies | Buy |
| 2020-12-16 | 개시 | Mizuho | Buy |
| 2020-09-29 | 개시 | BofA Securities | Underperform |
| 2020-09-10 | 개시 | Morgan Stanley | Overweight |
| 2020-04-28 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-14 | 개시 | Cowen | Outperform |
| 2019-12-30 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-17 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-16 | 재확인 | Guggenheim | Buy |
| 2019-10-16 | 개시 | Guggenheim | Buy |
| 2019-09-18 | 개시 | William Blair | Outperform |
| 2019-05-28 | 개시 | SunTrust | Buy |
| 2019-05-23 | 재확인 | H.C. Wainwright | Buy |
| 2019-04-08 | 개시 | SVB Leerink | Outperform |
| 2019-03-15 | 재확인 | H.C. Wainwright | Buy |
| 2016-10-03 | 재개 | Brean Capital | Buy |
| 2015-12-15 | 개시 | Cantor Fitzgerald | Buy |
| 2015-12-14 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Axsome Therapeutics Inc 주식(AXSM)의 최신 뉴스
Mark Jacobson Sells 4,517 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat
Insider Selling: Axsome Therapeutics (NASDAQ:AXSM) COO Sells 233 Shares of Stock - MarketBeat
Axsome Therapeutics COO Mark Jacobson sells $1.08m in stock - Investing.com
Axsome Therapeutics COO Mark Jacobson sells $1.08m in stock By Investing.com - Investing.com UK
Axsome Therapeutics (AXSM) reports Q1 loss, beats revenue estimates - MSN
AXSM Q1 Loss Widens, Revenues Jump on Higher Auvelity Sales - Yahoo Finance UK
Axsome Therapeutics (NASDAQ:AXSM) Stock Price Expected to Rise, Morgan Stanley Analyst Says - MarketBeat
Strong Drug Sales Lift Axsome Revenue, But Profit Miss Drags Stock - Sahm
Axsome Therapeutics Reports Strong Q1 2026 Results Driven by Revenue Growth and FDA Approval for AUVELITY - IndexBox
Wells Fargo & Company Boosts Axsome Therapeutics (NASDAQ:AXSM) Price Target to $255.00 - MarketBeat
Robert W. Baird Issues Positive Forecast for Axsome Therapeutics (NASDAQ:AXSM) Stock Price - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $310.00 at Mizuho - MarketBeat
B. Riley Adjusts Price Target on Axsome Therapeutics to $300 From $230, Maintains Buy Rating - marketscreener.com
Mizuho Adjusts Price Target on Axsome Therapeutics to $310 From $228, Maintains Outperform Rating - marketscreener.com
Axsome Therapeutics, Inc. $AXSM Shares Bought by UBS Group AG - MarketBeat
RBC Raises Price Target on Axsome Therapeutics to $302 From $242, Keeps Outperform Rating - marketscreener.com
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q1 2026 Earnings Call Transcript - Insider Monkey
Axsome Therapeutics 1Q Rev $191.2M >AXSM - Moomoo
Axsome Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Mizuho raises Axsome Therapeutics price target on Auvelity outlook - Investing.com
Mizuho raises Axsome Therapeutics price target on Auvelity outlook By Investing.com - Investing.com Canada
Axsome Wins FDA Nod For Expanded Use For Auvelity Beyond Depression - Sahm
B.Riley raises Axsome Therapeutics price target on sales guidance - Investing.com
B.Riley raises Axsome Therapeutics price target on sales guidance By Investing.com - Investing.com Canada
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Axsome Therapeutics 1Q Auvelity Net Product Sales $153.2M, Up 59% >AXSM - Moomoo
Axsome Therapeutics Earnings Call Signals Aggressive Growth - TipRanks
RBC Capital raises Axsome stock price target on higher revenue outlook By Investing.com - Investing.com South Africa
Axsome Therapeutics Q1 2026 earnings preview - MSN
Axsome projects Auvelity peak sales of at least $8B following Alzheimer's agitation approval and June launch - MSN
Baird raises Axsome Therapeutics stock price target on Auvelity launch By Investing.com - Investing.com Australia
AXSM Stock Is Rising Today After Wall Street’s Positive Stance Despite Mixed Q1 – What's Behind The Optimism? - Stocktwits
Axsome Therapeutics, Inc. 1Q 2026: Revenue $191.2M, EPS $(1.26) — 10-Q Summary - TradingView
Baird raises Axsome Therapeutics stock price target on Auvelity launch - Investing.com
RBC Capital raises Axsome stock price target on higher revenue outlook - Investing.com
Oppenheimer raises Axsome Therapeutics price target on Auvelity sales By Investing.com - Investing.com Australia
Axsome Therapeutics Reports Wider Than Expected Q1 2026 Loss - AlphaStreet
Oppenheimer raises Axsome Therapeutics price target on Auvelity sales - Investing.com
Why Did Axsome Therapeutics Stock Hit Another Record High Today? - The Globe and Mail
Axsome Therapeutics Inc Stock (AXSM) Moved Up by 10.20% on May 4: Facts Behind the Movement - TradingKey
Guggenheim raises Axsome stock price target to $260 on drug sales - Investing.com
AXSM Stock Jumps As FDA Clears Auvelity For Alzheimer’s Agitation - StocksToTrade
Axsome Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Axsome Q1 2026 slides: 57% revenue growth amid FDA approval milestone - Investing.com India
Axsome Therapeutics: Current Cash Sufficient to Fund Anticipated Operations Into Cash Flow Positivity >AXSM - Moomoo
Axsome Therapeutics 1Q Loss/Shr $1.26 >AXSM - Moomoo
TD Cowen raises Axsome stock price target on strong Q1 results By Investing.com - Investing.com South Africa
TD Cowen raises Axsome stock price target on strong Q1 results - Investing.com
Axsome Therapeutics, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Axsome Therapeutics Q1 2026 Earnings Review: Gains Mystify Me, But Can't Be Denied (AXSM) - Seeking Alpha
Why is Axsome therapeutics trending amid Nasdaq Composite Index gains? - Kalkine Media
Axsome Therapeutics Inc (AXSM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Axsome Therapeutics Inc 주식 (AXSM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Jacobson Mark L. | Chief Operating Officer |
May 05 '26 |
Option Exercise |
12.95 |
233 |
3,017 |
233 |
| Jacobson Mark L. | Chief Operating Officer |
May 04 '26 |
Sale |
227.94 |
4,517 |
1,029,605 |
0 |
| Jacobson Mark L. | Chief Operating Officer |
May 05 '26 |
Sale |
228.18 |
233 |
53,166 |
0 |
0.78%
3.01%
자본화:
|
볼륨(24시간):